申请人:Daiichi Pharmaceutical Co., Ltd.
公开号:US05232924A1
公开(公告)日:1993-08-03
A heterocyclic compound represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group, an aryl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom, an alkoxy group, an alkyl group and a trihalogenomethyl group; .lambda. represents 0 or 1; ring A represents a 6 membered heterocyclic ring containing the nitrogen atom shared with the triazine ring and which may contain one or more double bonds; Y represents a substituted or unsubstituted alkylene group having 1 to 15 carbon atoms; and Q represents a group represented by formula (II): ##STR2## wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are represented by substituents disclosed herein; or salt thereof, and intermediates therefor are described. The compound of formula (I) or salt thereof exhibit selective serotonin 2-receptor antagonistic activity and are useful for the prevention or treatment of circulatory diseases, e.g., ischemic heart diseases, cerebral vessel disturbances, and peripheral circulation disturbances.
一种由式(I)表示的杂环化合物:##STR1##其中R1表示氢原子、烷基组、可能被一个或多个选自卤素原子、烷氧基组、烷基组和三卤甲基组的取代基取代的芳基组;λ表示0或1;环A表示含有与三嗪环共用氮原子的6元杂环环,该环可能含有一个或多个双键;Y表示具有1至15个碳原子的取代或未取代的亚烷基组;Q表示由式(II)表示的组:##STR2##其中R2、R3、R4和R5由本文披露的取代基表示;或其盐,以及其中间体。式(I)的化合物或其盐表现出对血清素2受体的选择性拮抗活性,并可用于预防或治疗循环系统疾病,例如缺血性心脏病、脑血管障碍和外周循环障碍。